证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

Core Viewpoint - The announcement indicates a significant change in the ownership structure of Yiming Pharmaceutical, with the original controlling shareholder, Gao Fan, transferring 43.86 million shares (23% of total shares) to Beijing Fuhai, effective August 19, 2025, resulting in a new controlling shareholder and actual controller [1] Group 1 - Gao Fan will transfer 43.86 million shares, representing 23% of the company's total shares, to Beijing Fuhai [1] - After the transfer, Beijing Fuhai will become the controlling shareholder of Yiming Pharmaceutical [1] - The actual controller will change from Gao Fan to Yao Jinbo following the completion of the share transfer [1]

证券代码：002826 证券简称：易明医药 公告编号：2025-056 西藏易明西雅医药科技股份有限公司 关于控股股东、实际控制人股份协议转让完成过户登记 暨公司控制权发生变更的公告 高帆保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露 义务人提供的信息一致。 西藏易明西雅医药科技股份有限公司（以下简称"上市公司"、"公司"） 于近日收到高帆先生的通知，获悉其将持有的 43,855,883 股公司股份（占上市 公司股份总数的 23.00%）协议转让给北京福好企业管理合伙企业（有限合伙） （以下简称"北京福好"）事项已取得中国证券登记结算有限责任公司出具的《证 券过户登记确认书》。现将相关情况公告如下： 一、本次协议转让的基本情况 2025 年 5 月 31 日，公司原控股股东、实际控制人高帆与北京福好签署了《股 份转让协议》，以及于 2025 年 7 月 25 日签署了《股份转让协议之补充协议》， 北京福好拟协议收购高帆持有的 43,855,883 股公司股份，占上市公司股份总数 的 23.00%。 本次权益变动完成后，北京福好将持 ...

本次协议转让完成后，北京福好持有公司43,855,883股股份(占上市公司股份总数的23.00%)，为公司第 一大股东。公司控股股东由高帆变更为北京福好，实际控制人由高帆变更为姚劲波。 格隆汇8月20日丨易明医药(002826.SZ)公布，公司于近日收到高帆先生的通知，获悉其将持有的 43,855,883股公司股份(占上市公司股份总数的23.00%)协议转让给北京福好企业管理合伙企业(有限合伙) (简称"北京福好")事项已取得中国证券登记结算有限责任公司出具的《证券过户登记确认书》。 ...

Core Points - Yiming Pharmaceutical (002826) announced the transfer of 43.8559 million shares, representing 23% of the company's total shares, from Gao Fan to Beijing Fuhai Enterprise Management Partnership [2] - Following this transfer, Beijing Fuhai will become the controlling shareholder of the company, with the actual controller changing from Gao Fan to Yao Jinbo [2]

（文章来源：每日经济新闻） 易明医药（SZ 002826，收盘价：25.74元）8月20日晚间发布公告称，公司控股股东由高帆变更为北京 福好，实际控制人由高帆变更为姚劲波。 2025年1至6月份，易明医药的营业收入构成为：药品销售占比99.71%，其他占比0.58%，药品推广服务 占比-0.29%。 ...

Core Viewpoint - Yiming Pharmaceutical (002826.SZ) announced a significant change in its shareholding structure, with the original controlling shareholder, Gao Fan, transferring 43.86 million shares (23.00% of total shares) to Beijing Fuhai, effective August 19, 2025, resulting in a new controlling shareholder and actual controller, Yao Jinbo [1] Group 1 - The share transfer involves 43.86 million shares, representing 23.00% of the total shares of the company [1] - After the transfer, Beijing Fuhai will hold 43.86 million shares, becoming the new controlling shareholder [1] - The actual control of the company will shift from Gao Fan to Yao Jinbo following the completion of this equity change [1]

Group 1 - The core viewpoint of the news highlights the financial performance and stock activity of Yiming Pharmaceutical (002826) as of August 19, 2025, with a closing price of 24.39 yuan, reflecting a slight increase of 0.12% [1] - The company reported a total operating revenue of 311 million yuan for the first half of 2025, representing a year-on-year decrease of 11.52%, while the net profit attributable to shareholders was 37.56 million yuan, down 5.27% year-on-year [1] - The company’s non-recurring net profit showed significant growth, reaching 25.02 million yuan, which is an increase of 102.33% compared to the previous year [1] Group 2 - The company has a current ratio of 2.688 and a quick ratio of 2.474, indicating strong liquidity, with a debt-to-asset ratio of 23.32% [1] - Yiming Pharmaceutical has made investments in 6 companies and participated in 10 bidding projects, showcasing its active engagement in the market [2] - The company holds 11 trademark registrations and 16 patents, along with 15 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]

Core Insights - Yiming Pharmaceutical (SZ002826) reported a decline in both revenue and net profit for the first half of 2025, with revenue at 311.45 million yuan, down 11.52% year-on-year, and net profit attributable to shareholders at 37.56 million yuan, down 5.27% year-on-year [1][2]. Financial Performance - Revenue for the reporting period was 311,445,583.30 yuan compared to 351,984,809.03 yuan in the same period last year, reflecting an 11.52% decrease [2]. - Net profit attributable to shareholders was 37,557,144.18 yuan, down from 39,646,165.15 yuan, marking a 5.27% decline [2]. - Net profit after deducting non-recurring gains and losses was 25,022,156.54 yuan, which represents a significant increase of 102.33% from 12,366,829.01 yuan in the previous year [1][2]. - The net cash flow from operating activities was 62,458,414.18 yuan, an increase from 46,131,657.93 yuan year-on-year [2]. - Basic and diluted earnings per share were both 0.20 yuan, down from 0.21 yuan [2]. - The weighted average return on equity was 4.96%, slightly down from 5.30% [2]. Asset and Equity Position - Total assets at the end of the reporting period were 1,005,255,294.07 yuan, up from 926,469,234.87 yuan at the end of the previous year [2]. - Net assets attributable to shareholders were 764,048,582.94 yuan, an increase from 739,003,677.36 yuan [2]. Executive Compensation - The vice president of Yiming Pharmaceutical, Gao Ying, received a salary of 701,500 yuan, which is higher than the chairman's salary of 681,600 yuan and the general manager's salary of 614,300 yuan [1][2].

Core Viewpoint - 易明医药's stock closed at 23.35 yuan on August 15, experiencing a decline of 0.15 yuan or 0.64% from the previous trading day [1] Company Performance - For the first half of 2025, 易明医药 reported a revenue of 311 million yuan, representing a year-on-year decrease of 11.52% [1] - The net profit attributable to shareholders was 37.56 million yuan, down 5.27% year-on-year [1] - The company signed a compensation agreement with performance commitment parties, involving an amount of 14.43 million yuan [1] Market Activity - On August 15, the net inflow of main funds into 易明医药 was 19.95 million yuan, accounting for 0.49% of the circulating market value [1] - Over the past five days, the cumulative net inflow of main funds reached 199 million yuan, representing 4.89% of the circulating market value [1]